De Novo Ventures
De Novo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would have significant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by De Novo investment success in selected medical device and biotechnology companies.
With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. De Novo invest in all stages of enterprise development and growth – from early stage to late stage. De Novo unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
Eight exits have occurred in DNV I -- four IPOs: Favrille (NASDAQ: FVRL), Fox Hollow Technologies (NASDAQ: EVVV), Renovis (NASDAQ: RNVS), and SenoRx (NASDAQ: SENO) and four acquisitions: CryoVascular Systems (Boston Scientific), TriVascular (Boston Scientific), LuMend (Johnson and Johnson) and Microvention (Terumo). DNV II has had one exit to date – Hansen Medical (NASDAQ: HNSN).
Contact Details
Office Address
De Novo Ventures
2180 Sand Hill Road, Suite 200
Menlo Park, CA, USA 94025
Phone: (650) 329-1999
Fax: (650) 329-1315
Executives
Managing Director
Frederick J. (Fred) Dotzler
CFO
Cathy Minshall
.webp)
.webp)
.webp)
.webp)
.webp)
